Registry update — unassessed
Assessing the Role of GLP-1 Receptor Agonist Semaglutide and Dual GLP-I/GIP Receptor Agonist Tirzepatide in Delaying Genetic Aging in Adult Obese Patients Using the iWatchAge Technology
Trial registry update: RECRUITING. No results reported in the supplied registry record.
RCTN=66Minor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Dec 19, 2025 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract does not report any results, so it is unclear whether either GLP-1 agonist affected epigenetic aging or related biomarkers.
- The open-label design means participants and clinicians knew which treatment was given, creating potential for bias in subjective measures.
- The 24-week study period may be insufficient to detect meaningful changes in epigenetic aging, and comparison to metformin rather than placebo limits interpretation of drug-specific effects.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 66
- Duration
- 6 months
- Population
- Adults with simple obesity who have not used weight-loss medications for at least 3 months
- Primary outcome
- Changes in biological (epigenetic) age assessed using iWatchAge DNA methylation age test
- Effect size
- —
- Significance
- Not reported
- Journal
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Published
- Dec 19, 2025
Sources
Primary source
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
This study is a prospective, randomized, open-label clinical trial enrolling 66 adults with simple obesity who have not used weight-loss medications for at least 3 months.
Participants will receive semaglutide, tirzepatide, or metformin for 24 weeks.
Changes in 'biological (epigenetic) age' will be assessed using the iWatchAge DNA methylation age test, while simultaneously monitoring improvements in aging-related biomarkers such as inflammatory factors, metabolic parameters, and body composition.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.